FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagede.medizininformatikinitiative.kerndatensatz.mtb
Resource TypeClaim
IdClaim-MII-EXA-MTB-Antrag-Kostenuebernahme-1.json
FHIR VersionR4

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source


English


Generated Narrative: Claim MII-EXA-MTB-Antrag-Kostenuebernahme-1

Profile: MII PR MTB Antrag Kostenuebernahme version: 2027.0.0-ballot.1

status: Active

type: institutional

use: Claim

patient: Kim Musterperson (no stated gender), DoB: 1956-03-14

created: 2023-03-10

provider: Organization Example General Hospital

priority: Normal

Relateds

-Relationship
*initial-claim

prescription: MedicationRequest: extension = 1,Predictive value of the biomarker or clinical effectiveness of the corresponding drug in a molecularly stratified cohort was demonstrated in a prospective study or a meta-analysis in the same tumor type.,http://doi.org#10.1200/JCO.2022.40.16_suppl.5512,http://www.ncbi.nlm.nih.gov/pubmed#38055253; status = completed; intent = proposal; medication[x] = MIRVETUXIMAB SORAVTANSINE; authoredOn = 2023-03-28

CareTeams

-SequenceProviderResponsible
*1Organization Example Health Insurance Co.true

Insurances

-SequenceFocalCoverageClaimResponse
*1trueCoverage: status = active; type = extended healthcare; period = 2023-01-01 --> 2025-12-31ClaimResponse: status = active; type = institutional; use = claim; created = 2023-05-01; outcome = complete

German


Generated Narrative: Claim MII-EXA-MTB-Antrag-Kostenuebernahme-1

Profile: MII PR MTB Antrag Kostenuebernahme version: 2027.0.0-ballot.1

status: Active

type: institutional

use: Claim

patient: Kim Musterperson (no stated gender), DoB: 1956-03-14

created: 2023-03-10

provider: Organization Example General Hospital

priority: Normal

Relateds

-Relationship
*initial-claim

prescription: MedicationRequest: extension = 1,m1A,http://doi.org#10.1200/JCO.2022.40.16_suppl.5512,http://www.ncbi.nlm.nih.gov/pubmed#38055253; status = completed; intent = proposal; medication[x] = MIRVETUXIMAB SORAVTANSINE; authoredOn = 2023-03-28

CareTeams

-SequenceProviderResponsible
*1Organization Example Health Insurance Co.true

Insurances

-SequenceFocalCoverageClaimResponse
*1trueCoverage: status = active; type = extended healthcare; period = 2023-01-01 --> 2025-12-31ClaimResponse: status = active; type = institutional; use = claim; created = 2023-05-01; outcome = complete

Source1

{
  "resourceType": "Claim",
  "id": "MII-EXA-MTB-Antrag-Kostenuebernahme-1",
  "meta": {
    "profile": [
      "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-antrag-kostenuebernahme|2027.0.0-ballot.1"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "status": "active",
  "type": {
    "coding": [
      {
        "code": "institutional"
      }
    ]
  },
  "use": "claim",
  "patient": {
    "reference": "Patient/PatientKimMusterperson"
  },
  "created": "2023-03-10",
  "provider": {
    "reference": "Organization/MyHospital"
  },
  "priority": {
    "coding": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/processpriority",
        "code": "normal"
      }
    ]
  },
  "related": [
    {
      "relationship": {
        "coding": [
          {
            "code": "initial-claim"
          }
        ]
      }
    }
  ],
  "prescription": {
    "reference": "MedicationRequest/mii-exa-mtb-medication-request-mirvetuximab"
  },
  "careTeam": [
    {
      "sequence": 1,
      "provider": {
        "reference": "Organization/MyInsurer"
      },
      "responsible": true
    }
  ],
  "insurance": [
    {
      "sequence": 1,
      "focal": true,
      "coverage": {
        "reference": "Coverage/MyCoverage"
      },
      "claimResponse": {
        "reference": "ClaimResponse/MII-EXA-MTB-Antwort-Kostenuebernahme-1"
      }
    }
  ]
}